Baillie Gifford & Co’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-49
| Closed | -$7.38K | – | 268 |
|
|
2025
Q1 | $7.38K | Sell |
49
-75,362
| -100% | -$11.3M | ﹤0.01% | 261 |
|
|
2024
Q4 | $13.9M | Buy |
75,411
+6,826
| +10% | +$1.26M | 0.01% | 198 |
|
|
2024
Q3 | $13.5M | Buy |
68,585
+1,048
| +2% | +$206K | 0.01% | 200 |
|
|
2024
Q2 | $14M | Buy |
67,537
+3
| +0% | +$620 | 0.01% | 197 |
|
|
2024
Q1 | $18.3M | Sell |
67,534
-2,668
| -4% | -$723K | 0.01% | 193 |
|
|
2023
Q4 | $16.6M | Sell |
70,202
-9,370
| -12% | -$2.22M | 0.01% | 202 |
|
|
2023
Q3 | $15.6M | Sell |
79,572
-5,524
| -6% | -$1.08M | 0.01% | 196 |
|
|
2023
Q2 | $17.9M | Sell |
85,096
-394
| -0.5% | -$82.8K | 0.02% | 185 |
|
|
2023
Q1 | $17.3M | Buy |
85,490
+14,118
| +20% | +$2.85M | 0.02% | 191 |
|
|
2022
Q4 | $15.6M | Sell |
71,372
-527
| -0.7% | -$115K | 0.02% | 196 |
|
|
2022
Q3 | $14.2M | Buy |
71,899
+56,103
| +355% | +$11M | 0.01% | 201 |
|
|
2022
Q2 | $3.38M | Buy |
+15,796
| New | +$3.38M | ﹤0.01% | 256 |
|